Jason Karlawish of the Perelman School of Medicine says that patients need mild cognitive impairment or mild-stage dementia to be eligible for new Alzheimer’s drug lecanemab.

https://cbsn.ws/3CHUdsd January 6, 2023 CBS News (Sacramento)